Per previous comments to CMS, the Biologics Prescribers Collaborative wishes that each biosimilar would receive its own unique payment rate and HCPCS code. This graphic depicts that in order to trace side effects to their source, a unique billing code is required for each biological medicine. As physicians who make complex medical decisions daily, we are committed to principles of patient-centered care and a clinically-sound prescribing process for biological products, including biosimilars. The current CMS policy of assigning a single HCPCS billing code and reimbursement rate for all biosimilars of a single reference product seriously jeopardizes these principles, undermining innovation, science and safety.
Read more from the Alliance for Patient Access
